cognitieve achteruitgang cognitive decline
Conditions
Interventions
Subjects will receive 150 mg/kg body weight L-tyrosine powder or 50 mg/kg body
weight of dextrin-maltose with 100 mg/kg cornstarch (placebo condition) in a
randomized order. Both interventions will
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Aged 60-75 years - Right-handed - Dutch speaking - Normal or corrected to normal vision
Exclusion criteria
Exclusion criteria: - Mini-Mental State Examination (MMSE) score of 11 - Current or past psychiatric disorder, such as psychosis or major depression - Current or past neurological disorder, such as severe cerebral vascular disease (e.g. cortical stroke, subarachnoid hemorrhage), Parkinson*s disease, epilepsy, traumatic brain injury, central nervous system infection, brain tumor, and alcoholic encephalopathy. N.B. Transient Ischaemic Attack, lacunar infarction and white matter lesions are no exclusion criteria. - Current severe systemic disease such as coronary artery disease, myocardial infarction 160/90 mmHg (use of antihypertensives are allowed) - General medical conditions, such as repetitive strain injury (RSI), colorblindness or sensori-motor handicaps, which may confound the results of the study, as judged by the investigator - Alcohol consumption of more than 14 (women) or 21 (men) units per week - Habitual smoking, defined as more than a pack of cigarettes per week - Current participation in another study, or a specific cognitive training study within the past six months, or a study using the same cognitive paradigm as the current study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in functional prefrontal activation as determined by oxygenated hemoglobin changes (µmol/L) induced by tyrosine supplementation, measured during response inhibition performance. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Changes in functional prefrontal activation as determined by oxygenated hemoglobin changes (µmol/L) induced by tyrosine supplementation, measured during working memory performance. - Changes in functional prefrontal activation as determined by deoxygenated hemoglobin changes (µmol/L) induced by tyrosine supplementation, measured during response inhibition performance and working memory performance. - Changes in brain activity as determined by EEG frequency bands, induced by tyrosine supplementation, measured during response inhibition performance. - Effect of blood pressure (mmHg), exhaled CO2 (%) and heart rate on the oxygenated and deoxygenated hemoglobin changes. - Changes in behavioural performance on the response inhibition and working memory tasks, induced by tyrosine supplementation (preparatory slowing and stop-signal reaction time of stop-signal task and accuracy and reaction time of n-back task. - Changes in performance on the neuropsychological test battery, induced by tyrosine supplementation. | — |
Countries
Netherlands
Outcome results
None listed